Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Kim, Kyu-Tae; Lee, Hye; Lee, Hae-Ock; Song, Hye; Jeong, Da; Shin, Sang; Kim, Hyunho; Shin, Yoojin; Nam, Do-Hyun; Jeong, Byong; Kirsch, David; Joo, Kyeung; Park, Woong-Yang
• Is Part Of: Genome biology. Volume 17:Issue 1(2016)
• Page Start: 1
• Page End: 17
• Publication Date: 2016-12
• Subjects: Single cell analysis -- Renal cell carcinoma -- Patient-derived xenograft -- Tumor heterogeneity -- Drug response; Genomes -- Periodicals; Biology -- Periodicals; Molecular biology -- Periodicals; 572.8633
• DOI: 10.1186/s13059-016-0945-9
• Languages: English
• ISSNs: 1474-760X

Abstract

Abstract Background Intratumoral heterogeneity hampers the success of marker-based anticancer treatment because the targeted therapy may eliminate a specific subpopulation of tumor cells while leaving others unharmed. Accordingly, a rational strategy minimizing survival of the drug-resistant subpopulation is essential to achieve long-term therapeutic efficacy. Results Using single-cell RNA sequencing (RNA-seq), we examine the intratumoral heterogeneity of a pair of primary renal cell carcinoma and its lung metastasis. Activation of drug target pathways demonstrates considerable variability between the primary and metastatic sites, as well as among individual cancer cells within each site. Based on the prediction of multiple drug target pathway activation, we derive a combinatorial regimen co-targeting two mutually exclusive pathways for the metastatic cancer cells. This combinatorial strategy shows significant increase in the treatment efficacy over monotherapy in the experimental validation using patient-derived xenograft platformsin vitro andin vivo . Conclusions Our findings demonstrate the investigational application of single-cell RNA-seq in the design of an anticancer regimen. The approach may overcome intratumoral heterogeneity which hampers the success of precision medicine.